Results 11 to 20 of about 280,071 (239)

Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project

Haematologica, 2016
The distribution of non-Hodgkin lymphoma subtypes varies around the world, but a large systematic comparative study has never been done. In this study, we evaluated the clinical features and relative frequencies of non-Hodgkin lymphoma subtypes in five ...
Anamarija M. Perry, Jacques Diebold, Bharat N. Nathwani, Kenneth A. MacLennan, Hans K. Müller-Hermelink, Martin Bast, Eugene Boilesen, James O. Armitage, Dennis D. Weisenburger   +8 more
doaj   +2 more sources

Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents

Haematologica, 2016
Children and adolescents with pre-existing conditions such as DNA repair defects or other primary immunodeficiencies have an increased risk of non-Hodgkin lymphoma. However, large-scale data on patients with non-Hodgkin lymphoma and their entire spectrum
Andishe Attarbaschi, Elisa Carraro, Oussama Abla, Shlomit Barzilai-Birenboim, Simon Bomken, Laurence Brugieres, Eva Bubanska, Birgit Burkhardt, Alan K.S. Chiang, Monika Csoka, Alina Fedorova, Janez Jazbec, Edita Kabickova, Zdenka Krenova, Jelena Lazic, Jan Loeffen, Georg Mann, Felix Niggli, Natalia Miakova, Tomoo Osumi, Leila Ronceray, Anne Uyttebroeck, Denise Williams, Wilhelm Woessmann, Grazyna Wrobel, Marta Pillon   +25 more
doaj   +2 more sources

Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies

OncoTarget, 2017
Immune checkpoint blockade therapeutics, notably antibodies targeting the programmed death 1 (PD-1) receptor and its PD-L1 and PD-L2 ligands, are currently revolutionizing the treatment of cancer.
Pauline Gravelle, Barbara Burroni, Sarah Péricart, Cédric Rossi, Christine Bezombes, Marie Tosolini, Diane Damotte, Pierre Brousset, Jean‐Jacques Fournié, Camille Laurent   +9 more
openalex   +3 more sources

Epidemiology of Non-Hodgkin’s Lymphoma

Medical Science, 2021
Non-Hodgins’s lymphoma (NHL) is the most common hematological malignancy worldwide, accounting for nearly 3% of cancer diagnoses and deaths. NHL is the seventh most prevalent cancer and has the sixth highest mortality among cancers in the US.
K. Thandra, A. Barsouk, Kalyan Saginala, S. Padala, Alexander Barsouk, Prashanth Rawla   +5 more
semanticscholar   +1 more source

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.

New England Journal of Medicine, 2020
BACKGROUND Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited.
V. Minard-Colin, A. Aupérin, M. Pillon, G. Burke, D. Barkauskas, K. Wheatley, Rafael F Delgado, S. Alexander, A. Uyttebroeck, C. Bollard, J. Zsiros, M. Csóka, B. Kazanowska, A. Chiang, R. Miles, A. Wotherspoon, P. Adamson, G. Vassal, C. Patte, T. Gross   +19 more
semanticscholar   +1 more source

Frequent mutation of histone modifying genes in non-Hodgkin lymphoma

Nature, 2011
Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are the two most common non-Hodgkin lymphomas (NHLs). Here we sequenced tumour and matched normal DNA from 13 DLBCL cases and one FL case to identify genes with mutations in B-cell NHL ...
Ryan D. Morin, María Méndez-Lago, A. Mungall, R. Goya, K. Mungall, R. Corbett, N. Johnson, T. Severson, Readman Chiu, M. Field, S. Jackman, M. Krzywinski, D. Scott, Diane L. Trinh, Jessica Tamura-Wells, Sa Li, M. Firme, S. Rogic, M. Griffith, Susanna Y. Chan, Oleksandr Yakovenko, Irmtraud M. Meyer, E. Zhao, D. Smailus, M. Moksa, S. Chittaranjan, L. Rimsza, A. Brooks-Wilson, J. Spinelli, S. Ben-Neriah, B. Meissner, B. Woolcock, M. Boyle, H. McDonald, Angela Tam, Yongjun Zhao, Allen D. Delaney, Thomas Zeng, Kane Tse, Y. Butterfield, I. Birol, R. Holt, J. Schein, D. Horsman, Richard A. Moore, Steven J. M. Jones, J. Connors, M. Hirst, R. Gascoyne, M. Marra   +49 more
semanticscholar   +1 more source

Non-Hodgkin's lymphoma: A review

Journal of Family Medicine and Primary Care, 2020
Lymphomas constitute the third most common neoplasm in head and neck region arising from the lymphoreticular system. Malignant lymphomas are divided into Hodgkin's disease and non-Hodgkin's lymphoma (NHL).
Rohit Singh, S. Shaik, B. Negi, J. Rajguru, Pankaj Patil, Dr. Anuj S. Parihar, Uma Sharma   +6 more
semanticscholar   +1 more source

Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]

, 2016
Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S., Fanale, Michelle A., Fu, Siqing, Garrido-Laguna, Ignacio, Hong, David S., Janku, Filip, Kaseb, Ahmed O., Kurzrock, Razelle, Meric-Bernstam, Funda, Naing, Aung, Park, Haeseong, Patel, Shreyaskumar, Piha-Paul, Sarina A., Subbiah, Vivek, Tsimberidou, Apostolia M., Velez-Bravo, Vivianne M M., Wheler, Jennifer J., Zinner, Ralph G.   +17 more
core   +2 more sources

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

Journal of Clinical Oncology, 2019
PURPOSE Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies.
I. Flinn, Carole B. Miller, K. Ardeshna, S. Tetreault, S. Assouline, J. Mayer, M. Merli, S. Lunin, A. Pettitt, Z. Nagy, O. Tournilhac, K. Abou-Nassar, M. Crump, E. Jacobsen, S. de Vos, V. Kelly, Weiliang Shi, L. Steelman, N. Le, D. Weaver, S. Lustgarten, N. Wagner-Johnston, P. Zinzani   +22 more
semanticscholar   +1 more source

Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in non-Hodgkin lymphoma: a SIE, SIES, and GITMO consensus paper [PDF]

, 2016
Objectives: In this paper, we present a review of critical concepts and research perspectives and produce recommendations on the optimal use of pixantrone in non-Hodgkin lymphoma (NHL) by group discussion from an expert panel appointed by the Italian ...
Barosi, Giovanni, Corradini, Paolo, Martelli, Maurizio, Minotti, Giorgio, Oliva, Stefano, Spina, Michele, Tura, Sante, Zinzani, Pier Luigi   +7 more
core   +1 more source